Efficacy and Safety of LX9211 in Patients With Postherpetic Neuralgia

Status:
Recruiting

Trial end date:
2022-05-31

Target enrollment:

Participant gender:

Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.

Phase 2

Lexicon Pharmaceuticals